Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects

ClinicalTrials.gov ID: NCT00312494

Public ClinicalTrials.gov record NCT00312494. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Three-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Add-On Oral Ziprasidone in Subjects With Acute Mania Treated With Lithium or Divalproex

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

3-week study to evaluate efficacy and safety of ziprasidone with either lithium or divalproex in acutely manic subjects

Study identification

NCT ID
NCT00312494
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
680 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 2006 (Type not available)
Primary completion
Dec 2008 (Actual)
Completion
Dec 2008 (Actual)
Last update posted
Mar 29, 2021

2006 – 2008

United States locations

U.S. sites
66
U.S. states
25
U.S. cities
54
Facility City State ZIP Site status
Pfizer Investigational Site Dothan Alabama 36303 —
Pfizer Investigational Site Scottsdale Arizona 85251 —
Pfizer Investigational Site Little Rock Arkansas 72211 —
Pfizer Investigational Site Cerritos California 90703 —
Pfizer Investigational Site Costa Mesa California 92626 —
Pfizer Investigational Site Escondido California 92025 —
Pfizer Investigational Site Glendale California 91204 —
Pfizer Investigational Site Huntington Beach California 92647 —
Pfizer Investigational Site Los Angeles California 90057 —
Pfizer Investigational Site Los Angeles California 90061 —
Pfizer Investigational Site National City California 91950 —
Pfizer Investigational Site Oceanside California 92056 —
Pfizer Investigational Site San Diego California 92114 —
Pfizer Investigational Site San Diego California 92120 —
Pfizer Investigational Site San Diego California 92126 —
Pfizer Investigational Site Torrance California 90505 —
Pfizer Investigational Site Hartford Connecticut 06106 —
Pfizer Investigational Site New Britain Connecticut 06050 —
Pfizer Investigational Site DeLand Florida 32720 —
Pfizer Investigational Site Fort Lauderdale Florida 33301 —
Pfizer Investigational Site Fort Lauderdale Florida 33308 —
Pfizer Investigational Site Gainesville Florida 32607 —
Pfizer Investigational Site Hollywood Florida 33021 —
Pfizer Investigational Site Jacksonville Florida 32256-2006 —
Pfizer Investigational Site Lauderhill Florida 33119 —
Pfizer Investigational Site North Miami Florida 33161 —
Pfizer Investigational Site Atlanta Georgia 30308 —
Pfizer Investigational Site Honolulu Hawaii 96813 —
Pfizer Investigational Site Des Plaines Illinois 60016 —
Pfizer Investigational Site Hoffman Estates Illinois 60169 —
Pfizer Investigational Site Hoffman Estates Illinois 60194 —
Pfizer Investigational Site Schaumburg Illinois 60194 —
Pfizer Investigational Site Greenwood Indiana 46143 —
Pfizer Investigational Site Prairie Village Kansas 66206 —
Pfizer Investigational Site Glen Burnie Maryland 21061 —
Pfizer Investigational Site Flowood Mississippi 39232 —
Pfizer Investigational Site Kansas City Missouri 64133 —
Pfizer Investigational Site Saint Charles Missouri 63304 —
Pfizer Investigational Site St Louis Missouri 63044-2588 —
Pfizer Investigational Site St Louis Missouri 63118 —
Pfizer Investigational Site St Louis Missouri 63128 —
Pfizer Investigational Site Las Vegas Nevada 89102 —
Pfizer Investigational Site Las Vegas Nevada 89103 —
Pfizer Investigational Site Clementon New Jersey 08021 —
Pfizer Investigational Site Princeton New Jersey 08540 —
Pfizer Investigational Site Amityville New York 11701 —
Pfizer Investigational Site Buffalo New York 14215 —
Pfizer Investigational Site Cedarhurst New York 11516 —
Pfizer Investigational Site Elmsford New York 10523 —
Pfizer Investigational Site Raleigh North Carolina 27609 —
Pfizer Investigational Site Cincinnati Ohio 45219 —
Pfizer Investigational Site Cincinnati Ohio 45220 —
Pfizer Investigational Site Cincinnati Ohio 45267-0559 —
Pfizer Investigational Site Cleveland Ohio 44113 —
Pfizer Investigational Site Oklahoma City Oklahoma 73112 —
Pfizer Investigational Site Philadelphia Pennsylvania 19149 —
Pfizer Investigational Site Charleston South Carolina 29405 —
Pfizer Investigational Site Dallas Texas 75228 —
Pfizer Investigational Site Irving Texas 75062 —
Pfizer Investigational Site Plano Texas 75024 —
Pfizer Investigational Site San Antonio Texas 78229-3900 —
Pfizer Investigational Site San Antonio Texas 78259-3509 —
Pfizer Investigational Site Richmond Virginia 23229 —
Pfizer Investigational Site Richmond Virginia 23230 —
Pfizer Investigational Site Bellevue Washington 98004 —
Pfizer Investigational Site Kirkland Washington 98033 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00312494, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 29, 2021 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00312494 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →